Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Muntean, W; Borkenstein, M.
Haemostatic changes in tall girls treated with high doses of ethinyloestradiol.
Eur J Pediatr. 1980; 134(3):245-248
Doi: 10.1007/BF00441480
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Muntean Eugen
- Co-Autor*innen der Med Uni Graz
- Borkenstein Helmuth Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Haemostasis was studied in 8 tall girls during treatment with high doses of synthetic oestrogens for a period of 1 to 28 months. The girls received 0.5 mg ethinyloestradiol daily from day 1 to day 25 and 15 mg norethisteron daily from day 21 to day 25. All were without clinical signs of thromboembolism. Factors of the prothrobmin complex were significantly elevated in the tall girls compared to healthy controls of the same age. Fibrinogen was also significantly elevated. Factor VIII-related antigen was significantly higher in the tall girls and the ratio between factor VIII activity and factor VIII-related antigen was significantly decreased in the tall girls, as compared to the controls. Thrombin time was significantly shortened. Tests of primary haemostasis showed an increased tendency for thrombocytes to adhere to glass and to aggregate spontaneously and after stimulation with ADP or collagen. Whether these in vitro signs of hypercoagulability indicate an enhanced risk of throbmoembolic complications in tall girls treated with high doses of oestrogens remains to be established. However, these girls should be watched carefully for clinical signs of throbmoembolic complications during treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Blood Coagulation -
- Body Height -
- Ethinyl Estradiol - therapeutic use
- Factor VIII - analysis
- Female - analysis
- Fibrinogen - analysis
- Growth Disorders - drug therapy
- Humans - drug therapy
- Norethindrone - therapeutic use
- Platelet Adhesiveness - therapeutic use
- Thrombin Time - therapeutic use